$MRK
MRK · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for MRK…
AI-generated for information only — not investment advice.
Share this ticker
$MRK Stanley Druckenmiller and 1 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/MRK
Company summary
Keytruda maker and vaccines.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest MRK news
- Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Mon, 07 Sep 2026 11:02:00 +0000
- Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
Fri, 04 Sep 2026 21:45:02 +0000
- Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.
Thu, 03 Sep 2026 21:27:34 +0000
- Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
Thu, 03 Sep 2026 16:00:00 +0000
- The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
Tue, 08 Sep 2026 01:49:14 +0000
- Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE
Mon, 07 Sep 2026 17:00:00 +0000
- Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Thu, 03 Sep 2026 16:47:00 +0000
- Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
Mon, 07 Sep 2026 17:00:45 +0000